(Medical Xpress)—Recently some intriguing data has suggested that breast cancer patients whose tumors appear insensitive to a class of drugs known as anti-HER2 medications (the drug trastuzumab, marketed as Herceptin, is ...
Nov 18, 2013
not rated yet | 0 |
A nontoxic hydrogel developed by the A*STAR Institute of Bioengineering and Nanotechnology and IBM Research offers a new way forward for breast cancer therapeutics.
Dec 04, 2013
5 / 5 (1) | 0